Cardioprotective effectiveness of SGLT2 inhibitors in older diabetic women with early-stage breast cancer following anthracycline- and/or trastuzumab-based treatment.

Although there was a tendency toward lower point estimates for the cardiovascular composite endpoint and incident HF or CM in the SGLT2i group compared to the OAM group, the differences in the risk for all CV outcomes did not reach statistical significance ( Supplemental Tables 3 and 4 ).

also in 111,027 other papers

Consistent with findings from the ITT analysis, a nonsignificant trend toward a reduced risk estimate was observed for the composite CVD and new HF or CM diagnosis.

also in 5,406 other papers